Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Radium-223: An alternative treatment for prostate cancer

04.06.2007
The bone-targeting radioisotope radium-223 has delivered promising results in a randomised trial to test its efficacy in treatment of hormone-refractory prostate cancer (HRPC). The findings are reported early Online - timed to coincide with presentation of the paper at the American Society of Clinical Oncology meeting in Chicago – and in an upcoming edition of The Lancet Oncology.

Patients who have HRPC often have involvement of bone marrow, leading to symptoms such bone pain, spinal-cord compression and pathological fracture. Existing bone-targeted treatments, such as use of the beta-emitting radioisotope strontium-89 have been shown to reduce bone pain.

Dr Christopher Parker, Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK and colleagues did a study of 64 patients with HRPC. Radium 223 was chosen because it emits alpha radiation – which has higher energy and travels less distance than the beta radiation. Thus Parker and colleagues believe that alpha radiation will have a more pronounced localised effect on tumours.

The patients were randomly assigned to two groups. In the first, 33 received external-beam radiotherapy and up to four injections of radium-223. The other group received the same radiotherapy and placebo.

Levels of bone alkaline phosphatase (bone-ALP) – considered a marker for progression of HRPC – decreased by 66% in the group receiving radium-223. The length of time for patients’ HRPC to progress - as assessed by each prostate-specific-antigen concentration – was much longer for those receiving radium 223 (26 weeks) compared to placebo (eight weeks). The median survival time for radium-223 patients was 41% longer than those receiving placebo (65.3 weeks vs 46.4 weeks respectively); and no Radium-223 patients stopped treatment due to treatment toxicity

However, radium-223 treatment had no significant effect on the timing of skeletal related events (SREs) – another key indicator of HRPC progression. These include, among other factors, a 25% increase in pain severity, increased painkiller consumption, new pathological bone fractures, tumour related orthopaedic surgical intervention, and use of radioisotopes to relieve new skeletal related symptoms.

The authors believe larger clinical trials are needed to study the effect of radium-223 on SREs and overall survival rates for HRPC.

The authors say: “In our randomised study of patients with symptomatic, hormone-refractory prostate cancer, radium-223 was well tolerated with little or no myelotoxic effect, and showed promising evidence of efficacy.”

They conclude: “Further studies of radium-223 should explore potential for escalation of dose and for increased duration of treatment by more than four injections. The bone targeting properties of Radium-223 could also be applicable to the treatment of skeletal metastasis from other primary cancers.”

Tony Kirby | alfa
Further information:
http://www.lancet.com

More articles from Health and Medicine:

nachricht NTU scientists build new ultrasound device using 3-D printing technology
07.12.2016 | Nanyang Technological University

nachricht How to turn white fat brown
07.12.2016 | University of Pennsylvania School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

NTU scientists build new ultrasound device using 3-D printing technology

07.12.2016 | Health and Medicine

The balancing act: An enzyme that links endocytosis to membrane recycling

07.12.2016 | Life Sciences

How to turn white fat brown

07.12.2016 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>